Absci (ABSI) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Absci (ABSI) has outperformed MaxCyte (MXCT) over the past year, gaining 156.3% versus a loss of 18.0%. Over five years, ABSI leads with a -31.8% price change compared with -85.9% for MXCT. Absci is the larger company by market cap ($1.30 billion vs $141.5 million), about 9.2 times the size, while MaxCyte is growing revenue faster (-14.5% vs -38.2%).
MaxCyte converts more of its revenue into profit, with a net margin of -135.1% versus -4113.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | MXCT |
|---|---|---|
| Share price | $7.51 | $1.37 |
| Market cap | $1.30B | $141.45M |
| 1-day change | -7.97% | +7.03% |
| YTD return | +115.19% | -11.61% |
| 1-year return | +156.31% | -17.96% |
| 5-year return | -31.79% | -85.92% |
| EPS (TTM) | $-0.79 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $33.03M |
| Revenue growth (YoY) | -38.24% | -14.50% |
| Net income (latest FY) | $-115.18M | $-44.63M |
| Gross margin | — | 81.16% |
| Operating margin | -4297.04% | -157.14% |
| Net margin | -4113.68% | -135.14% |
| 52-week high | $12.55 | $1.80 |
| 52-week low | $2.24 | $0.643 |
| Distance from 52-week high | -40.14% | -23.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +100.93% | +200.00% |
| Average volume | 4.08M | 1.04M |
| Shares outstanding | 172.75M | 103.25M |
| Employees | 140 | 91 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Absci is about 9.2 times larger than MaxCyte by market value ($1.30B vs $141.45M).
- ABSI has outperformed MXCT by 174.3 percentage points over the past year.
- MaxCyte is more profitable, keeping -135.1 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
- MaxCyte grew revenue faster in its latest fiscal year (-14.50% vs -38.24%).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
ABSI vs MXCT FAQ
Which is bigger, Absci or MaxCyte?
Absci (ABSI) is larger, with a market capitalization of $1.30B compared with $141.45M for MaxCyte (MXCT).
Which stock has performed better over the past year, ABSI or MXCT?
ABSI returned +156.31% over the past 12 months, compared with -17.96% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are Absci and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.